Merck, Inc.
First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension Study
- Conditions
- Esophageal Neoplasms
- Interventions
- First Posted Date
- 2019-03-19
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT03881111
- Locations
- 🇨🇳
Peking Union Medical College Hospital ( Site 0123), Beijing, Beijing, China
🇨🇳Guangdong General Hospital ( Site 0103), Guangzhou, Guangdong, China
🇨🇳The Affiliated Tumour Hospital of Harbin Medical University ( Site 0102), Harbin, Heilongjiang, China
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 125
- Registration Number
- NCT03875092
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, China
Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)
- Conditions
- Renal DialysisKidney Failure, Chronic
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 38
- Registration Number
- NCT03873038
- Locations
- 🇺🇸
New Orleans Center for Clinical Research ( Site 0001), Knoxville, Tennessee, United States
🇺🇸Prism Research ( Site 0003), Saint Paul, Minnesota, United States
🇺🇸Orlando Clinical Research Center ( Site 0002), Orlando, Florida, United States
Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Drug: Placebo
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 950
- Registration Number
- NCT03867084
- Locations
- 🇧🇪
UZ Leuven ( Site 0377), Leuven, Vlaams-Brabant, Belgium
🇺🇸City of Hope Medical Center ( Site 0027), Duarte, California, United States
🇦🇷Fundación favaloro para la Docencia e Investigación Médica ( Site 0808), Buenos Aires, Caba, Argentina
Safety, Tolerability, Pharmacokinetics, and Anti-Retroviral Activity of MK-8558 Monotherapy in Anti-Retroviral-Naïve HIV-1 Infected Participants (MK-8558-002)
- First Posted Date
- 2019-03-01
- Last Posted Date
- 2021-05-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 21
- Registration Number
- NCT03859739
- Locations
- 🇷🇴
Matei Bals Infectious Diseases Institute ( Site 0002), Bucharest, Bucuresti, Romania
🇩🇪Charite Research Organisation GmbH ( Site 0001), Berlin, Germany
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2023-09-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 262
- Registration Number
- NCT03850444
Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)
- Conditions
- Pneumococcal Infections
- Interventions
- Biological: Pneumococcal 13-valent Conjugate Vaccine (PCV13)Biological: Adsorbed Diphtheria-purified Pertussis-tetanus-inactivated polio (Sabin strain) Combined Vaccine (DTaP-IPV)
- First Posted Date
- 2019-02-20
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 133
- Registration Number
- NCT03848065
- Locations
- 🇯🇵
Kubota Children's Clinic ( Site 2815), Osaka, Japan
🇯🇵Japanese Red Cross Shizuoka Hospital ( Site 2817), Shizuoka, Japan
🇯🇵Hosaka Children's Clinic ( Site 2814), Tokyo, Japan
Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)
- Conditions
- Varicella
- Interventions
- Biological: VARIVAX™
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 150
- Registration Number
- NCT03843632
- Locations
- 🇷🇺
Republican Clinical Infectious Hospital n.a. A.F. Agafonov ( Site 5816), Kazan, Russian Federation
🇷🇺Research Institute of Children Infections ( Site 5801), Saint Petersburg, Russian Federation
🇷🇺SPb Pasteur RI of Epidemiology and Microbiology ( Site 5817), Saint Petersburg, Russian Federation
Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)
- Conditions
- Cytomegalovirus Infections
- Interventions
- Biological: V160Other: Placebo
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT03840174
- Locations
- 🇯🇵
Souseikai PS Clinic ( Site 0001), Fukuoka, Japan
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)
- Conditions
- Prostatic Neoplasms
- Interventions
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1030
- Registration Number
- NCT03834506
- Locations
- 🇨🇦
Lakeridge Health ( Site 0117), Oshawa, Ontario, Canada
🇨🇦Sunnybrook Research Institute ( Site 0108), Toronto, Ontario, Canada
🇺🇸Mount Sinai Hospital Medical Center ( Site 0042), Chicago, Illinois, United States